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This “Cell and Tissue Research” Special Issue focuses on 
the cell biology of neurotrophic factors. Why this is impor-
tant? Neurotrophic factors (NTFs) are secreted proteins that 
by binding to their specific receptors on the plasma mem-
brane of neurons activate intracellular signalling pathways 
that regulate several key aspects of neuronal structure and 
function as well as survival. Four classes of neurotrophic 
factors have been characterized so far. The oldest is the 
neurotrophin family represented by the first growth factor 
described – nerve growth factor (NGF)—and by the most 
studied trophic factor brain-derived neurotrophic factor 
(BDNF). Other members of the neurotrophin family are 
neurotrophin-3 (NT-3) and neurotrophin-4 (NT-4/5).
The second family of NTFs is heralded by the glial cell 
line-derived neurotrophic factor (GDNF) whose biology has 
been much studied, in part because it has special relevance 
to dopamine neurons of the substantia nigra pars compacta 
that degenerate in Parkinson’s disease. Several clinical trials 
have explored GDNF actions in Parkinson’s disease patients. 
Other members of the GDNF family of ligands (GFLs) are 
neurturin (NRTN), artemin (ARTN) and persephin (PSPN). 
The most recent addition to the family, Growth/Differentia-
tion Factor 15 (GDF15), shows structural similarity and uses 
the same receptor system as other members of the GDNF 
family.
The neuropoetic cytokine (neurokine) family (also known 
as interleukin 6 (IL-6)) or glycoprotein 130 (GP130) consists 
of several factors, of which the best known are IL-6, ciliary 
neurotrophic factor (CNTF) and the cardiotropins 1 and 2 
(CT1 and CT2).
The cerebral dopamine neurotrophic factor (CDNF)—
mesencephalic astrocyte-derived neurotrophic factor 
(MANF) (CDNF-MANF)—family of neurotrophic factors 
is the newest defined and evolutionarily most conserved. 
Interestingly, this family differs significantly from the others 
by its members acting not only after secretion but also, and 
mostly, inside the cells in the endoplasmic reticulum.
Neurotrophin, GFL and neurokine family members sig-
nal through the transmembrane receptor tyrosine kinases or 
through receptors that interact with kinases. The specific 
neuronal populations responsive to neurotrophic factors 
express cognate receptors at the cell surface whose activa-
tion acts through well-defined pathways to trigger a wide 
variety of biological responses. Events are registered in the 
cytosol, ranging from changes in the synthesis and traffick-
ing of intracellular proteins and vesicles, as well as in the 
nucleus with potent effects in regulating transcription. NTF 
signalling is best understood in the context of the cells in 
which they signal to regulate proliferation, differentiation, 
migration, axonal growth, survival of developing neurons, 
maintenance of adult neurons, and synaptic plasticity. Neu-
rotrophic factors are thus crucial for the development, physi-
ological regulation and maintenance of the nervous system, 
but also act on non-neuronal cells.
Since NTFs regulate neuronal survival, regeneration 
and responses to toxic exposure and injury, they have been 
evaluated as candidate drugs for the treatment of various 
neurological diseases, including neurodegenerative diseases 
such as Alzheimer’s disease, Parkinson’s disease and Amyo-
trophic Lateral Sclerosis (ALS). Remarkably, fully 30 years 
after initiating the first clinical trials with NTFs none have 
been approved for treating patients. Indeed a recently con-
cluded series of trials employing antibodies to NGF for 
Osteoarthritis may be the first to achieve approval for an 
NTF-related treatment. One of the reasons for such slow pro-
gress is limited knowledge about the cell biology of NTFs, 
especially in the context of brain aging and disease. Why 
is there such a knowledge gap? There are several reasons. 
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Firstly, the nervous system is by far the most complex organ; 
the brain harbors  1011 neurons engaged in at least  1014 syn-
aptic contacts. NTFs thus act to instruct and support a com-
plex machine whose functions are highly diverse. Secondly, 
neurons are postmitotic cells taxed by the need to adapt their 
function – i.e. to demonstrate plasticity and achieve homeo-
stasis – in the context of a changing external environment 
as well as to systemic changes, such as those that occur with 
normal and disease-related aging. This implies that actions 
of NTFs are often context-dependent and can thus not be 
readily generalized to all developmental stages and through-
out all brain areas. A key feature of context is location. It is 
increasingly recognized that studying secretion and actions 
of NTFs must consider the neuronal compartment(s) – i.e. 
context – in which the events are triggered. Thirdly, neuronal 
morphology is rather unique with long axons and dendrites. 
For example, in the case of midbrain dopamine neurons as 
many as 500,000 synaptic contacts are sustained at rela-
tively great distances from the neuron cell body. Neuron 
cell bodies are thus charged with overcoming the logistical 
challenges for supplying the molecular machinery needed 
to support distant synapses. NTF actions are thus tailored to 
support neurons in meeting these challenges. Fourthly, the 
physiological and anatomical burdens imposed upon neuron 
function come with extraordinary energy needs, especially 
those necessitated by the firing of action potentials and 
long distance trafficking of vesicles and molecular cargoes. 
Indeed, possibly most challenging is the need to initiate and 
respond to chemical and electrical signals acting at synapses 
whose structure and function vary greatly. NTFs play critical 
roles in enabling neurons to meet each of these challenges 
and thus to secure their ability to function over many dec-
ades in some mammals.
This Special Issue attempts to summarize current knowl-
edge on the cell biology of NTFs. It comprehensively 
addresses: NTF synthesis, processing, secretion, receptor 
activation, and endocytosis, downstream signalling, and 
actions in supporting neuronal growth, maintenance, syn-
aptic plasticity, and survival, as well as changes in NTF biol-
ogy posed by disease.
Two papers describe the current state of knowledge 
regarding synthesis, trafficking and release of BDNF. The 
paper by Brigadski and Leßmann (2020) comprehensively 
reviews each of several important features, and points to 
a diverse set of neuronal and non-neuronal cells that par-
ticipate in BDNF synthesis and release. Indeed, several 
cell types in brain and the periphery serve as sources of 
BDNF. One interesting perspective is the possibility that 
BDNF released from CNS neurons may act on cells outside 
the brain, and vice versa. Within the brain, it is clear that 
neurons as well as astrocytes and microglia can all serve as 
a source for BDNF. Equally significant is the perspective 
that both development and cellular context are important 
for defining the mechanisms and loci for BDNF release. The 
paper by Kojima and colleagues (2020) explores the biology 
of BDNF with an emphasis on the methods now available for 
detecting and measuring the relatively small amounts pre-
sent in and released from cells. Loci for BDNF release can 
now be interrogated much more effectively and both pre- and 
postsynaptic domains are clearly engaged. Furthermore, the 
synaptic machinery for release is now much better defined. 
Taken together these papers highlight emerging data point-
ing to the complexity and specificity of mechanisms that 
regulate BDNF availability for its responsive cells.
Andreska and colleagues (2020) focus on regulation of 
TrkB surface expression as a major factor for modulating 
neuronal responsiveness to BDNF. Pointing to co-factors 
such as cAMP, N-glycosylation and contributions from G 
protein-coupled receptors (GPCR) to explain signaling dif-
ferences between TrkB and other Trk family members, the 
authors review contexts wherein intracellular TrkB pools 
are rapidly mobilized to surface membranes, for example at 
pre- and post-synapses in response to activity. One particu-
larly interesting locus of BDNF action is the dendritic spine. 
BDNF has key roles during the lifetime of dendritic spines, 
from biogenesis to maintenance and plasticity, and spanning 
embryonic development and the adult. Zagrebelsky et al. 
(2020) review the roles of BDNF in modulating synapse 
number, structure and plasticity via apparently opposing 
roles of its receptors, TrkB and  p75NTR, with consequences 
for learning/memory, emotional regulation, and age and 
disease-related cognitive impairment. As an example for 
the complex involvement of BDNF pathways in regulating 
learning and memory processes, Meis and colleagues (2020) 
describe the current knowledge how BDNF signalling in 
amygdala neuronal circuits steers fear learning and fear 
extinction. Taking into account intra-amygdalar expression 
and release of BDNF but also release at thalamic and corti-
cal inputs to the basolateral amygdala (BLA), the authors 
try to disentangle how proBDNF/p75NTR and mBDNF/TrkB 
signalling in glutamatergic principle cells and GABAergic 
interneurons of the amygdala, respectively, shape fear mem-
ories in cooperation with hippocampal and cortical synaptic 
circuits.
Johnstone and Mobley (2020) take up the issue of BDNF 
actions in shaping activity of neuronal circuits by empha-
sizing that BDNF/TrkB signalling can considerably differ 
between distinct neuronal compartments even within the 
same cell. Moreover, by pinpointing the different well-
known intracellular signalling cascades downstream of TrkB 
activation, the authors lead us through changing aspects of 
these signalling events during neuronal development, initial 
circuit formation, and synaptic plasticity-dependent memory 
formation in adulthood.
Several reviews discuss GDNF and the cell biology of its 
receptors. John M. Spitsbergen and his team discuss GDNF 
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synthesis, secretion and internalization and focus on cellular 
events activated by GDNF on motoneurons (Cintrón-Colón 
et al., 2020). Masahide Takashashi discovered the RET 
proto-oncogene and he and his colleague present a com-
prehensive view of GFL signalling via the RET receptor 
(Kawai and Takahashi, 2020). Carlos F. Ibañéz originally 
demonstrated that GDNF can signal RET-independently and 
identified NCAM as one of the receptors used by GFLs. In 
the current review Ibañéz and colleagues (2020) summarize 
current knowledge on GFL non-RET signalling, focusing 
mostly on cellular effects. Donnelly & Pierchala (2020) dis-
cuss the role of plasma membrane and the localization of 
GFL receptor components in GFL signaling and crosstalk 
with other neurotrophic factor receptors and how trafficking 
of GFL receptor components potently influence the function 
of these other neurotrophic factors. They stress that complex 
signaling interactions are to be considered when evaluating 
the potential pathophysiological roles of RET, Trks and p75 
in cancer and neurodegenerative disorders.
GDNF has prominent survival promoting and neu-
rorestorative effects on midbrain dopamine neurons that 
degenerate in Parkinson’s disease. Although the effects of 
exogenously added GDNF on dopamine neurons are very 
well documented, the role of endogenous GDNF and its 
receptors GFRα1 and RET are still under investigation. 
Edgar Kramer and colleagues (2020) discuss the phenotypes 
in knockout mice for GDNF and its receptors’. Importantly, 
this review summarizes data on the crosstalk of GFLs with 
genes mutated in familial forms of Parkinson’s disease, such 
as PINK1, Alpha-synuclein, DJ-1, etc. Don Gash pioneered 
GDNF clinical trials in Parkinson’s disease (PD) patients 
and in this review he summarizes the results of GDNF clini-
cal trials and explores the reasons why the clinical benefit of 
GDNF treatment failed to meet specified clinical endpoints 
(Gash et al. 2020). Gene therapy employing neurturin in 
clinical trials in PD also failed to demonstrate efficacy. In 
order to improve therapeutic efficacy, several groups have 
used site-directed mutagenesis and gene technology to pro-
duce GDNF and NRTN variants with improved therapeutic 
properties. Pia Runeberg-Roos and Richard Penn in their 
review (2020) summarize biochemical and animal data for 
improving the therapeutic potential of mutated GDNF family 
ligands. GFL proteins are not ideal for the treatment of neu-
rological diseases, mainly because they do not pass through 
the blood–brain barrier and therefore should be delivered 
directly into the brain using complicated neurosurgery. To 
overcome this limitation small molecules that mimic the 
action of GFLs have been developed. In the review by Arun 
Mahato and Yulia Sidorova (2020), recent progress in devel-
oping small molecule RET agonists for the treatment of pain 
and Parkinson’s disease is discussed.
As mentioned above CDNF-MANF family is an uncon-
ventional family of NTFs that signal mostly inside the cells 
regulating ER stress, but as these proteins are also secreted 
into the extracellular space, there is another mode of signal-
ling that is initiated from the plasma membrane. In their 
review Brandon Harvey and his colleague discuss recent 
progress in CDNF and MANF signalling in the ER (Jäntti 
and Harvey 2020).
Overall, this special issue brings together the expert cur-
rent knowledge on the biology of NTFs. Topics range from 
the role of BDNF in synaptic plasticity and how it contrib-
utes to memory formation, to cutting edge information on 
the signalling cascades employed by diverse GDNF neuro-
trophic factor family members, and to many new insights 
into the unconventional cellular actions of CDNF-MANF 
family neurotrophic factors. Now, many decades after the 
discovery of the first NTF and nearly four decades after the 
appreciation of the existence of many additional NTFs act-
ing on a host of target cells, we embark on an era in NTF 
research – one in which new tools and concepts will guide 
us to a more incisive understanding of NTF actions in the 
normal nervous system and a more comprehensive appre-
ciation of how they feature in the biology of disease. Our 
shared hope is that this will also be an era unprecedented 
for the creation of approaches to exploit NTFs as treatments 
for neurodegenerative diseases.
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